GOSS
Gossamer Bio, Inc. NASDAQ Listed Feb 8, 2019$0.34
Mkt Cap $80.7M
52w Low $0.32
0.7% of range
52w High $3.87
50d MA $0.41
200d MA $2.04
P/E (TTM)
-0.5x
EV/EBITDA
-5.4x
P/B
—
Debt/Equity
-1.6x
ROE
138.8%
P/FCF
-4.1x
RSI (14)
—
ATR (14)
—
Beta
2.16
50d MA
$0.41
200d MA
$2.04
Avg Volume
16.5M
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
3013 Science Park Road · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | AMC | -0.20 | -0.21 | -5.0% | 0.47 | -3.0% | -8.0% | +4.1% | -6.5% | -11.6% | -7.6% | — |
| Nov 5, 2025 | AMC | -0.19 | -0.21 | -10.5% | 2.37 | -3.8% | -2.5% | +2.2% | +5.1% | +4.4% | +4.2% | — |
| Aug 5, 2025 | AMC | -0.18 | -0.17 | +5.6% | 2.16 | +0.9% | -8.3% | -12.1% | +1.1% | -1.1% | +10.9% | — |
| May 15, 2025 | AMC | -0.18 | -0.16 | +11.1% | 1.05 | +0.0% | -1.0% | +4.8% | +8.3% | -2.5% | +0.9% | — |
| Mar 13, 2025 | AMC | -0.17 | -0.15 | +11.8% | 1.30 | +3.1% | +11.5% | -4.1% | +2.2% | -4.2% | -0.7% | — |
| Nov 7, 2024 | AMC | -0.18 | -0.14 | +22.2% | 0.89 | -1.9% | -0.9% | -2.4% | -1.2% | -3.8% | -5.6% | — |
| Aug 12, 2024 | AMC | 0.23 | 0.22 | -4.3% | 0.80 | +3.9% | +3.8% | +0.2% | -0.3% | +3.1% | +9.8% | — |
| May 7, 2024 | AMC | -0.19 | -0.19 | +0.0% | 0.73 | +5.1% | +3.3% | -1.3% | -0.4% | -3.0% | +1.8% | — |
| Mar 5, 2024 | AMC | -0.20 | -0.21 | -5.0% | 1.45 | +0.0% | +4.1% | -7.9% | -0.7% | -2.9% | +4.5% | — |
| Nov 9, 2023 | AMC | -0.20 | -0.21 | -5.0% | 0.55 | +2.9% | -4.8% | +20.2% | -1.1% | +30.2% | +1.8% | — |
| Aug 8, 2023 | AMC | -0.49 | -0.45 | +8.2% | 1.22 | +3.3% | -1.6% | +0.0% | -2.5% | +0.0% | -2.6% | — |
| May 9, 2023 | AMC | -0.55 | -0.52 | +5.5% | 1.36 | +2.9% | +3.7% | -4.3% | -11.1% | -0.8% | -2.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $0.42 | $0.40 | -5.3% | -11.6% | -7.6% | +10.6% | -1.8% | -7.6% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.52 | $0.51 | -1.7% | -4.0% | +10.9% | -8.7% | -3.4% | -6.1% |
| Mar 5 | Oppenheimer | Maintains | Outperform → Outperform | — | $0.58 | $0.57 | -1.7% | -10.0% | -4.0% | +10.9% | -8.7% | -3.4% |
| Feb 24 | Wedbush | Downgrade | Outperform → Neutral | — | $0.42 | $0.39 | -8.3% | -1.9% | -8.5% | +5.8% | +5.7% | +0.9% |
| Feb 24 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $0.42 | $0.39 | -8.3% | -1.9% | -8.5% | +5.8% | +5.7% | +0.9% |
| Feb 24 | Barclays | Downgrade | Overweight → Underweight | — | $0.42 | $0.39 | -8.3% | -1.9% | -8.5% | +5.8% | +5.7% | +0.9% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.74 | $2.79 | +1.8% | +4.7% | -5.9% | -1.5% | -0.8% | -3.4% |
| Sep 11 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.11 | $3.18 | +2.3% | +11.3% | +0.0% | -8.1% | +0.6% | -6.6% |
| Sep 10 | UBS | Upgrade | Neutral → Buy | — | $2.77 | $2.99 | +7.9% | +12.3% | +11.3% | +0.0% | -8.1% | +0.6% |
| Aug 6 | Wedbush | Maintains | Outperform → Outperform | — | $2.16 | $2.18 | +0.9% | -8.3% | -12.1% | +1.1% | -1.1% | +10.9% |
| May 16 | Wedbush | Maintains | Outperform → Outperform | — | $1.05 | $1.05 | +0.0% | -1.0% | +4.8% | +8.3% | -2.5% | +0.9% |
| May 16 | Goldman Sachs | Maintains | Buy → Buy | — | $1.05 | $1.05 | +0.0% | -1.0% | +4.8% | +8.3% | -2.5% | +0.9% |
| Apr 17 | Goldman Sachs | Maintains | Buy → Buy | — | $0.83 | $0.82 | -1.2% | +1.5% | -3.5% | +1.8% | +8.1% | +9.4% |
| Mar 14 | Wedbush | Maintains | Outperform → Outperform | — | $1.30 | $1.34 | +3.1% | +11.5% | -4.1% | +2.2% | -4.2% | -0.7% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.92 | $0.93 | +0.7% | +4.9% | +3.1% | +3.7% | -1.0% | +12.7% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.88 | $0.87 | -1.0% | -2.4% | -1.2% | -3.8% | -5.6% | -3.9% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.91 | $0.92 | +0.8% | -1.2% | +1.4% | +5.3% | +9.4% | -4.8% |
| Aug 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.86 | $0.88 | +1.9% | +2.0% | -1.2% | -1.0% | +11.9% | -5.3% |
| Aug 13 | Wedbush | Maintains | Outperform → Outperform | — | $0.80 | $0.83 | +3.9% | +3.8% | +0.2% | -0.3% | +3.1% | +9.8% |
| Jun 17 | Goldman Sachs | Maintains | Buy → Buy | — | $0.52 | $0.53 | +2.1% | +0.0% | +4.3% | +4.8% | +14.3% | +27.1% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.69 | $0.71 | +2.3% | -1.5% | -1.9% | -4.7% | -0.3% | -2.7% |
| May 8 | Wedbush | Maintains | Outperform → Outperform | — | $0.73 | $0.77 | +5.1% | +3.3% | -1.3% | -0.4% | -3.0% | +1.8% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.74 | $0.75 | +1.3% | +5.5% | -6.3% | +3.3% | -1.3% | -0.4% |
| Mar 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.23 | $1.23 | +0.0% | -4.9% | +0.9% | +7.6% | -9.4% | -3.5% |
| Mar 6 | Wedbush | Maintains | Outperform → Outperform | — | $1.45 | $1.45 | +0.0% | +4.1% | -7.9% | -0.7% | -2.9% | +4.5% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.45 | $1.45 | +0.0% | +4.1% | -7.9% | -0.7% | -2.9% | +4.5% |
| Mar 6 | Goldman Sachs | Maintains | Buy → Buy | — | $1.45 | $1.45 | +0.0% | +4.1% | -7.9% | -0.7% | -2.9% | +4.5% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.85 | $0.87 | +2.4% | +8.2% | +7.2% | +1.4% | -7.3% | +5.0% |
| Dec 19 | Wedbush | Maintains | Outperform → Outperform | — | $0.85 | $0.85 | +0.0% | +5.4% | -5.3% | +4.9% | -3.5% | +0.6% |
| Nov 10 | Wedbush | Maintains | Outperform → Outperform | — | $0.55 | $0.57 | +2.9% | -4.8% | +20.2% | -1.1% | +30.2% | +1.8% |
| Aug 11 | Wedbush | Maintains | Outperform → Outperform | — | $1.20 | $1.19 | -0.8% | -2.5% | +0.0% | -2.6% | -5.3% | -5.6% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.20 | $1.23 | +2.5% | +0.0% | -2.5% | +0.0% | -2.6% | -5.3% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.25 | $1.26 | +0.8% | +0.8% | -4.0% | +5.8% | +5.5% | +3.0% |
| Jul 26 | Wedbush | Maintains | Outperform → Outperform | — | $1.25 | $1.26 | +0.8% | +0.8% | -4.0% | +5.8% | +5.5% | +3.0% |
| Jul 21 | Wedbush | Maintains | Outperform → Outperform | — | $1.24 | $1.30 | +4.8% | +8.9% | -0.7% | -6.7% | +0.8% | -4.0% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.41 | $1.39 | -1.4% | -4.3% | -11.1% | -0.8% | -2.5% | +13.8% |
| Mar 21 | Barclays | Maintains | Equal Weight → Equal Weight | — | $1.21 | $1.19 | -1.7% | -1.7% | -6.7% | -3.6% | +11.2% | +5.9% |
| Mar 7 | Raymond James | Downgrade | Outperform → Market Perform | — | $1.74 | $1.63 | -6.3% | -4.0% | -15.0% | -6.3% | -1.5% | +6.9% |
| Mar 1 | Guggenheim | Maintains | Neutral → Neutral | — | $1.73 | $1.67 | -3.5% | -4.0% | +6.0% | +4.0% | -4.9% | -4.0% |
| Dec 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.16 | $2.13 | -1.4% | -0.5% | +0.9% | +0.5% | +6.9% | +4.7% |
| Dec 7 | Barclays | Downgrade | Overweight → Equal Weight | — | $2.36 | $1.79 | -24.2% | -8.5% | -0.5% | +0.9% | +0.5% | +6.9% |
| Dec 7 | Goldman Sachs | Maintains | Buy → Buy | — | $2.36 | $1.79 | -24.2% | -8.5% | -0.5% | +0.9% | +0.5% | +6.9% |
| Dec 7 | UBS | Maintains | Buy → Buy | — | $2.36 | $1.79 | -24.2% | -8.5% | -0.5% | +0.9% | +0.5% | +6.9% |
| Dec 7 | SVB Leerink | Maintains | Outperform → Outperform | — | $2.36 | $1.79 | -24.2% | -8.5% | -0.5% | +0.9% | +0.5% | +6.9% |
| Dec 7 | SMBC Nikko | Downgrade | Outperform → Neutral | — | $2.36 | $1.79 | -24.2% | -8.5% | -0.5% | +0.9% | +0.5% | +6.9% |
| Dec 7 | Raymond James | Maintains | Outperform → Outperform | — | $2.36 | $1.79 | -24.2% | -8.5% | -0.5% | +0.9% | +0.5% | +6.9% |
| Dec 7 | JP Morgan | Downgrade | Neutral → Underweight | — | $2.36 | $1.79 | -24.2% | -8.5% | -0.5% | +0.9% | +0.5% | +6.9% |
| Nov 17 | Raymond James | Maintains | Outperform → Outperform | — | $9.23 | $9.19 | -0.4% | -1.2% | +0.2% | +2.7% | -3.7% | -0.1% |
| Oct 20 | Goldman Sachs | Maintains | Buy → Buy | — | $12.32 | $12.70 | +3.1% | +4.5% | -2.4% | -3.9% | -0.5% | -1.8% |
| Sep 21 | JP Morgan | Maintains | Neutral → Neutral | — | $13.60 | $13.31 | -2.1% | -7.6% | -2.2% | -1.1% | -0.7% | +3.0% |
No insider trades available.
8-K
Unknown — 8-K Filing
Gossamer Group faces delisting risk from Nasdaq due to low stock price but has 180 days to cure the deficiency through a reverse split or other remediation measures.
Apr 9
8-K
Unknown — 8-K Filing
Gossamer Bio's seralutinib partnership with Chiesi Group and clinical progress in PAH/PH-ILD treatment could drive revenue growth and reduce development costs, making the stock attractive if trials succeed.
Mar 17
8-K · 8.01
!! High
Gossamer Bio, Inc. -- 8-K 8.01: Material Event / Announcement
Gossamer Bio's seralutinib failed to meet primary efficacy endpoints in Phase 3 PROSERA trial for pulmonary arterial hypertension, likely triggering significant stock decline and program reassessment.
Feb 23
Data updated apr 25, 2026 12:02pm
· Source: massive.com